(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...

Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®. Liraglutide is ...

Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Biocon Ltd has received US FDA approval for its complex formulation Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). The drug-device combination is indicated ...

Approval of the once-daily injection, as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access. (HealthDay News) — The US Food and Drug Administration has ...